Amylin is not a single receptor target
Amylin (IAPP) is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells in response to a meal. It promotes satiety, slows gastric emptying and suppresses postprandial glucagon, signalling mainly through the area postrema and nucleus tractus solitarius in the brainstem. This is a neural pathway distinct from the hypothalamic and pancreatic actions of GLP-1, which is why the two mechanisms are studied together.
One hormone, three receptors
Amylin does not bind a single receptor. It activates a family of receptors formed by the calcitonin receptor (CALCR) paired with one of three receptor-activity-modifying proteins (RAMP1, RAMP2, RAMP3), giving the subtypes AMY1R, AMY2R and AMY3R. The compound class divides on how broadly it engages this family.
Selective AMYR versus DACRA
A selective amylin-receptor agonist is engineered to activate AMYR with little or no calcitonin-receptor activity. Petrelintide (Zealand/Roche) and eloralintide (Eli Lilly), a peptide reported at roughly 50–100-fold selectivity for AMYR over CALCR, sit in this group. A dual amylin-and-calcitonin receptor agonist (DACRA) activates both receptors; cagrilintide, the amylin component of CagriSema, is a DACRA, as are earlier-stage compounds such as ABBV-295 and KBP-042.
The distinction matters because calcitonin-receptor engagement brings C-cell and thyroid monitoring considerations that a selective AMYR agonist is designed to avoid. The selectivity thesis also predicts a cleaner gastrointestinal profile, though that remains a hypothesis under test rather than an established clinical difference.
Tolerability is the engineering problem that defined the class
Amylin's first marketed analogue, pramlintide, signalled that the mechanism works but was limited by nausea rates above 30% and three-times-daily injection; it was a commercial failure. The current generation solved the half-life problem through acylation — attaching fatty-acid side chains so the peptide binds albumin and clears over days to weeks — enabling once-weekly dosing.
The UK position
No amylin-receptor agonist is licensed in the UK for weight management. Cagrilintide exists only inside the investigational CagriSema combination; petrelintide, eloralintide and the DACRAs are research compounds. Under the Medicines Act 1968 and the Human Medicines Regulations 2012, supplying an unlicensed medicine is a criminal offence, and none of these compounds holds an MHRA marketing authorisation. Peptide Data describes the research only; nothing here is guidance on human use, dosing or supply.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.